 |
Filgrastim |
|---|---|
| Trade Name | Neupogen |
| Orphan Indication | Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia |
| USA Market Approval | USA |
| USA Designation Date | 1996-11-07 00:00:00 |
| Sponsor | Amgen, Inc.;One Amgen Center Dr.;Thousand Oaks, California, 91320 |
